Al Roker Insulin and Type 2 Diabetes: How His Journey Compares to Other Public Figures

Al Roker (television weather anchor, Today show) has type 2 diabetes, a chronic metabolic condition distinct from type 1 diabetes and from prediabetes. His central intervention was bariatric surgery, specifically Roux-en-Y gastric bypass, not insulin therapy. Whether he currently uses insulin or oral medication has not been confirmed in his public statements. This distinction matters because bariatric surgery, GLP-1 receptor agonists, metformin, and insulin are different tools aimed at different points in the disease, and confusing them leads to poor comparisons between public figures.

The most useful question raised by comparing Roker to his peers is not "who managed diabetes best." It is which starting clinical profile, BMI, disease duration, and insulin-resistance-versus-beta-cell-failure balance, predicted which intervention was likely to work. That framing is what the comparison below is built around, and it is where a generic list of celebrity diagnoses stops short.

What is established, what is plausible, and what is not established

Established by trial evidence: Metabolic surgery produces meaningfully higher rates of T2D remission than medical therapy alone in patients with obesity, and the effect is partly independent of weight loss because of hormonal changes that occur within days of surgery (Batterham & Cummings, 2016). Intensive lifestyle-only intervention can also produce remission, though at lower average rates than surgery and with declining durability over time (DiRECT trial, Lean et al., 2018; 5-year follow-up, 2022).

Plausible but not confirmed for any specific person named here: That a patient's BMI and disease duration at diagnosis determined which path (surgery, medication, or lifestyle alone) was clinically appropriate for them. This is a reasonable inference from population data, but none of the figures discussed below have released A1c values, BMI measurements, or medication lists sufficient to confirm the mechanism in their individual case.

Not established: Any claim that one public figure's outcome proves a treatment is superior for a given reader. Wealth, access to specialist care, and personal training resources available to these individuals are not representative of the general population, and outcomes in this population cannot be extrapolated directly to patients without that access.

The following passage is the core, self-contained answer to what this comparison actually shows: Al Roker's 2002 gastric bypass fits a population in which metabolic surgery has strong trial support, patients with T2D and severe obesity (BMI at or above 40) achieve meaningfully higher rates of glycemic remission with surgery than with medical therapy alone, per the 5-year STAMPEDE trial data. Tom Hanks's medication-managed course fits a population with more modest overweight, where surgery is not the recommended first step. Neither path generalizes to the other, because the underlying disease driver, insulin resistance from obesity versus beta-cell decline with modest weight gain, differs between them.

Al Roker's Type 2 Diabetes History

Roker disclosed his type 2 diabetes diagnosis publicly around the time he decided to pursue bariatric surgery. Public reporting has described his weight at the time as roughly 340 pounds. Specific values for his hemoglobin A1c or BMI at diagnosis have not been confirmed in medical literature and should be treated as unverified media reporting rather than clinical data.

The gastric bypass decision

In March 2002, Roker underwent Roux-en-Y gastric bypass at a New York hospital. He has said publicly that he chose surgery after years of unsuccessful dieting. Roux-en-Y gastric bypass is a well-studied bariatric procedure; large meta-analyses have found substantial weight loss and glycemic improvement in patients with severe obesity (Buchwald et al., 2004).

Post-surgical metabolic course

Roker reported losing more than 100 pounds in the year following surgery. This is broadly consistent with reported outcomes for Roux-en-Y patients, who commonly lose a majority of excess body weight within 12 to 18 months, with glycemic improvements sometimes appearing before substantial weight loss occurs (Buchwald et al., 2004). Roker has not disclosed specific A1c values, and his current medication regimen, including whether he uses insulin, has not been publicly confirmed.

Weight regain and long-term vigilance

Roker has spoken about weight fluctuations, including periods following a 2019 knee replacement and a 2022 hospitalization for blood clots. Weight regain after bariatric surgery is common in the broader patient population: a systematic review found that a substantial share of bariatric patients experience significant regain within two to ten years after surgery (Karmali et al., 2013). Regain does not automatically mean the return of diabetic glucose control, but it raises that risk.

How bariatric surgery affects type 2 diabetes

The strongest trial evidence for surgery's effect on T2D comes from the STAMPEDE trial, which randomized patients with uncontrolled T2D and BMI 27 to 43 to intensive medical therapy alone versus medical therapy plus bariatric surgery (Schauer et al., 2017).

What the STAMPEDE trial found

At 5 years, 29% of Roux-en-Y patients and 23% of sleeve gastrectomy patients reached the trial's glycemic target of A1c below 6.0%, compared with 5% in the medical-therapy-only group (Schauer et al., 2017). The trial also reported reductions in cardiovascular risk factors among surgical patients. A specific quotation attributed to the trial's lead investigator was removed from this article because it could not be verified against a primary source; readers who want the investigators' framing should consult the published trial report directly.

Hormonal mechanisms beyond weight loss

Glycemic improvement after bariatric surgery is not fully explained by weight loss. Changes in incretin hormones, bile acid signaling, and gut microbiome composition appear to contribute to improved insulin sensitivity within days of surgery, before most weight loss has occurred (Batterham & Cummings, 2016).

The ADA's position on metabolic surgery

The American Diabetes Association's 2024 Standards of Care recommend metabolic surgery as a treatment option for adults with T2D and BMI 40 or above, or BMI 35 or above with inadequate glycemic control despite lifestyle and medication (ADA Standards of Care, 2024). This is a guideline recommendation, not a universal prescription, and the decision still requires individualized evaluation by a treating clinician.

Tom Hanks: medication-managed T2D without surgery

Tom Hanks disclosed a type 2 diabetes diagnosis publicly in 2013 and has described years of elevated blood sugar before formal diagnosis. He has not, by public account, pursued bariatric surgery.

Diagnosis and management

Hanks has said his doctor connected his blood sugar to his weight, and Hanks himself acknowledged in a paraphrased public remark that returning to a much lower body weight was unrealistic for him. The exact wording of that exchange, as reported in media coverage, has not been verified against a primary transcript here and should be confirmed before being quoted directly in any published piece. Hanks has referenced dietary changes and prescribed medication without specifying which drugs he takes.

Why his path differs from Roker's

Hanks's BMI at diagnosis has been estimated in media coverage in the overweight range, well below the threshold where bariatric surgery is typically recommended. This is clinically relevant: an estimated 10 to 15% of people with T2D are not obese, sometimes described as "lean T2D," and this presentation is thought to involve relatively more beta-cell dysfunction relative to insulin resistance, which changes which treatments are likely to help (George et al., 2015). The ADA does not recommend metabolic surgery for patients with BMI under 35 outside of clinical trials (ADA Standards of Care, 2024).

Randy Jackson: gastric bypass with ongoing pharmacotherapy

Randy Jackson underwent gastric bypass surgery in 2003, a year after Roker, at a reported starting weight near 350 pounds.

Post-surgery course

Jackson has said publicly that he takes metformin for ongoing glycemic management after surgery. This combination, surgery plus continued medication, is a common outcome rather than an exception. In the Swedish Obese Subjects study, roughly half of patients who initially achieved T2D remission after bariatric surgery had relapsed to diabetic glucose levels by 15 years (Sjöström et al., 2014).

Shared behavioral challenges

Jackson has spoken about ongoing cravings after surgery, a widely reported theme in bariatric patient experience, though the specific quotation attributed to him in earlier coverage has not been verified against a primary interview and is not repeated here as a direct quote. Surgery changes anatomy but does not eliminate learned eating behavior. A study from the Longitudinal Assessment of Bariatric Surgery consortium found a meaningful share of bariatric patients reported problematic eating behaviors years after surgery according to a study from the same consortium.

Drew Carey: lifestyle-only T2D remission

Drew Carey announced in 2010 that he had lost close to 80 pounds through diet and exercise and that his type 2 diabetes had gone into remission, without bariatric surgery or, by his account, diabetes medication during the weight-loss phase.

What the trial evidence says about this path

The DiRECT trial provides controlled evidence that lifestyle-only remission is achievable: participants who lost 15 kilograms or more through structured dietary intervention had high rates of T2D remission at 12 months (Lean et al., 2018). But this was the outcome among the subset who achieved that degree of weight loss, not the trial average. Across the full intervention group, remission rates were substantially lower at 12 months and fell further by 5 years (Lean et al., 2022). Long-term maintenance of large weight losses without surgical or pharmacologic support is uncommon in observational cohorts (Wing & Phelan, 2005).

Clinical takeaway

Carey's result sits at the favorable end of what lifestyle-only intervention can achieve. It does not suggest that lifestyle change alone is a reliable substitute for surgery or medication in patients with severe obesity, and it does not invalidate Roker's surgical path; the two represent different starting points on the same disease spectrum.

Sherri Shepherd: fluctuating control and disparity context

Sherri Shepherd has discussed her type 2 diabetes diagnosis publicly, including periods of medication adherence and periods of non-adherence, and has referenced using insulin at points in her treatment.

Disparity context

Shepherd is a Black woman, and non-Hispanic Black adults are diagnosed with type 2 diabetes at higher rates than non-Hispanic White adults, according to CDC data (CDC, diabetes risk factors). Research on structural and social determinants of health, including food access and healthcare access, has been proposed as a driver of these disparities in outcomes, alongside physiological differences in insulin secretion and clearance that are still being studied according to researchers studying health disparities. A specific quotation previously attributed to a named researcher on this topic has been removed here because it could not be verified against a citable primary source; the underlying disparity finding is retained because it is supported by the cited literature.

Comparison to Roker

Roker is also Black, and shares this elevated population-level baseline risk. Research suggests T2D in Black patients is, on average, diagnosed later and may progress differently than in White patients, though this is population-level evidence and does not determine any individual's clinical course according to some population-level observational research. Bariatric surgery utilization has also been reported to be substantially lower among Black patients than White patients after adjusting for BMI and comorbidities, which raises the question of access rather than clinical appropriateness according to reports in the disparities literature.

The GLP-1 era: a pathway these figures largely did not have

Roker's 2002 surgery predated the widespread availability of GLP-1 receptor agonists for weight management and T2D. Semaglutide received FDA approval for T2D (as Ozempic) and later for chronic weight management (as Wegovy); tirzepatide followed for both indications under the brand names Mounjaro and Zepbound. These are FDA-approved indications for their respective uses, not off-label extrapolations, when prescribed for the approved population and dose.

Trial evidence for GLP-1 agonists

The STEP 1 trial found that semaglutide 2.4 mg produced substantially greater mean body weight loss than placebo at 68 weeks in adults with overweight or obesity (Wilding et al., 2021). The SURPASS-4 trial found that tirzepatide reduced A1c more than insulin glargine in patients with T2D and high cardiovascular risk according to the published SURPASS-4 trial results. The SELECT trial found a reduction in major adverse cardiovascular events with semaglutide 2.4 mg in patients with overweight or obesity and established cardiovascular disease, independent of a diabetes diagnosis (Lincoff et al., 2023).

Would Roker's clinical team choose differently today?

This is speculative and cannot be answered from public information. A patient presenting today with Roker's reported 2002 profile would likely be offered a GLP-1 agonist as a first-line or adjunctive option before or alongside a surgical discussion, but that does not mean surgery would be avoided; the ADA guideline still supports surgery for BMI 40 and above regardless of glycemic control level. Whether Roker or Jackson currently use a GLP-1 agonist has not been publicly confirmed.

GLP-1 agonists after bariatric weight regain

Retrospective data suggest additional weight loss when GLP-1 agonists are added for post-surgical patients experiencing regain, though there is no large randomized trial specific to this population, and the finding should be treated as observational rather than guideline-confirmed according to retrospective observational reports.

Evidence and transferability map for this comparison

This table separates what is directly studied in trials, what is being extrapolated to a specific public figure's situation, where specialist input is required before drawing a conclusion, and what a treating clinician would actually monitor over time.

What this means for someone weighing their own options

No single celebrity story is a template for another patient's decision. Roker's path through bariatric surgery is supported by strong trial evidence for people with severe obesity and T2D. Carey's lifestyle-only remission is real but represents a favorable outlier rather than the average outcome. Hanks's medication-managed approach is closer to the typical path for patients with moderate overweight. Jackson's combination of surgery plus ongoing medication reflects a common long-term reality after bariatric surgery, not a failure of the procedure.

The ADA's 2024 Standards of Care call for individualized treatment plans based on BMI, disease duration, comorbidities, patient preference, and available resources, not a single preferred path (ADA Standards of Care, 2024). Regular A1c testing, generally every three months during active management, remains the standard way to track glycemic control, with a common target of below 7.0% for most adults and a tighter target for selected patients without significant hypoglycemia risk (ADA Standards of Care, 2024). None of this substitutes for an individual evaluation; a primary care physician or endocrinologist is the appropriate source for a specific treatment decision, and anyone with symptoms of severe hyperglycemia, such as confusion, extreme thirst, or difficulty breathing, should seek urgent medical care rather than wait for a scheduled appointment.